COVID Long-Haul

4

Review clinical trials related to COVID Long-Haul. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Covid-19 Long Immunité IMagerie (CLIIM)

Covid-long pathology affects a large number of patients, and represents a major medical, economic and societal challenge. To date, we have no objective criterion for a definitive diagnosis, nor any predictive tool for monitoring the evolution of Covid-long. Based on recruitment from the infectious diseases department of Nice University Hospital, the investigator's team wants to conduct an innovative pathophysiological study to better define the disease and identify specific biomarkers that could subsequently be used as a diagnostic tool for Covid-long. 120 participants will be initially included for the model learning phase: 60 controls in the CL- cohort and 60 patients in the CL+ cohort. Then 80 patients (40 CL+ and 40 Cl-) will be enrolled for the model validation phase.

Participants needed: 200
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Centre Hospitalier Universitaire de NiceUpdated: Jun 22, 2026Locations: 1
Eligibility criteria

Case definition in line with WHO Delphi process

History of chronic fatigue syndrome diagnosed before or after Covid. [+9]

Status: Recruiting

Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)

The purpose of this study is to test the effect of Auricular Percutaneous Electrical Nerve Field Stimulation (a Neurostim device) on children with pain and Post Concussion symptoms. An additional purpose of this study is to demonstrate that PENFS improves functioning in children with post Covid-19 symptoms.

Participants needed: 125
Trial details
Age: 11-18Biological sex: AllType: InterventionalSponsor: Children's Hospital of Orange CountyUpdated: Mar 18, 2026Locations: 1
Eligibility criteria

Clinical diagnosis of Post-Concussion Syndrome [+2]

Seizure disorders [+9]

Status: Recruiting

Mind Body Intervention for Long COVID-19

The goal of this study is to determine if a mind-body intervention can help people suffering from symptoms associated with Long COVID. The study is a randomized trial examining the effectiveness of a mind body intervention in reducing somatic symptoms from Long COVID in participants as compared to usual care and an active control (second mind body intervention). The investigators will secondarily investigate whether the intervention alleviates individual somatic complaints and improves daily functioning, relative to usual care and the active control

Participants needed: 180
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: Beth Israel Deaconess Medical CenterUpdated: Feb 18, 2026Locations: 1
Eligibility criteria

Adult (≥ 18 years of age) [+5]

Clear diagnosis of physical disease (e.g. lung fibrosis, myocarditis) not inclus... [+5]

Status: Recruiting

Long-Covid-19 Alleviation Through Learning Mindfulness Study

This research is being done to study a mindfulness intervention among people who have symptoms of Post-Acute Sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Mindfulness is defined as paying attention to the present moment with non-judgment and acceptance. Here the investigators are studying whether a mindfulness intervention can help reduce stress, reduce Long COVID symptoms, and improve quality of life among people living with Long COVID. The mindfulness intervention is a series of recorded mindfulness sessions, which were created by the study team. People who decide to take part will be randomly assigned to receive the study mindfulness intervention immediately after joining the study or to receive the study mindfulness intervention 8 weeks after joining the study. All participants will continue their usual medical care. Participants will complete online surveys to measure symptoms over time. The study will last 6 months.

Participants needed: 400
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Columbia UniversityUpdated: Aug 24, 2025Locations: 1
Eligibility criteria

Age > or = 18 [+4]

Participating in another clinical trial of an intervention for PASC symptoms [+1]